Difference between revisions of "Evaluation of suspected malignancies"

From patholines.org
Jump to navigation Jump to search
Line 87: Line 87:
 
<gallery mode=packed>
 
<gallery mode=packed>
 
File:Histopathology of endometrial cancer with lymphovascular invasion.jpg|Endometrial cancer with lymphovascular invasion.
 
File:Histopathology of endometrial cancer with lymphovascular invasion.jpg|Endometrial cancer with lymphovascular invasion.
File:Histopathology of typical micropapillary urothelial carcinoma infiltrating the lamina propria - crop.jpg|If unsure whether a case is true lymphovascular invasion or a retraction artifact (imaged), use immunohistochemistry for D2-40.
+
File:Histopathology of typical micropapillary urothelial carcinoma infiltrating the lamina propria - crop.jpg|If unsure whether a case is true lymphovascular invasion or a retraction artifact (imaged), use immunohistochemistry for D2-40 to highlight lymphatic vessels or CD-31 for blood vessels.
 
</gallery>
 
</gallery>
  

Revision as of 13:20, 30 October 2021

Author: Mikael Häggström [note 1]

General notes edit

Further reading:

For evaluation of suspected malignancies' such as tumors, the most important aspect is whether it is benign or malignant. If malignant, then staging is necessary.[1] There are generally specific criteria for various forms of tumors, which should be used whenever applicable, but following are some generalizations.

A general approach is to start looking at the slide which seems to contain most tumor (excluding any necrosis), facilitating a diagnosis, and shows what kind of cells to look for in the periphery.

Benign or malignant

Benign[2] Malignant[2]
Gross examination
  • Well demarcated from surrounding tissue
  • Usually no tumor capsule

Possibly:

  • Necrosis
  • Infiltration or invasion into surrounding tissue
  • Bleeding
Microscopy Almost no irregularities of cellular structures Nuclear atypia:
  • Enlargement
  • Pleomorphism
  • Nuclear polychromasia, which means variability in nuclear chromatin content.
  • Numerous mitotic figures

Overall diagnosis

For specific diagnoses by organ system, see anatomic map on Patholines Main page.

Two relatively common forms of tumors are:

Gland-like tumors are mainly evaluated for cellular atypia, architectural dysplasia and invasion, and thereby classified into the following main categories:

  • Hyperplastic lesions, lacking significant atypia
  • Adenomas, which can range from mild to high-grade dysplastic, yet are not invasive
  • Adenocarcinomas, with the main criterion being invasiveness. Evaluate specifically by location when possible:

For Spindle-cell tumors, the shape of the nuclei is a clue to the diagnosis, with the following tendency:

  • Pointed on both ends: True fibroblastic tumors
  • Pointed on one end and blunted on the other ("bullet-shaped"): Neural
  • Blunted on both ends ("cigar-shaped"): Smooth muscle
  • Triangular: Myofibroblastic

Staging

Staging is generally done by TNM classification. Specific TNM systems should be used, such as as per the manual by the American Joint Committee on Cancer (AJCC), whenever applicable. Otherwise, a general system may be used:[1]

T: size or direct extent of the primary tumor

    • Tx: tumor cannot be assessed
    • Tis: carcinoma in situ
    • T0: no evidence of tumor
    • T1, T2, T3, T4: size and/or extension of the primary tumor

N: degree of spread to regional lymph nodes

    • Nx: lymph nodes cannot be assessed
    • N0: no regional lymph node metastasis
    • N1: regional lymph node metastasis present; at some sites, tumor spread to closest or small number of regional lymph nodes
    • N2: tumor spread to an extent between N1 and N3 (N2 is not used at all sites)
    • N3: tumor spread to more distant or numerous regional lymph nodes (N3 is not used at all sites)

M: presence of distant metastasis

    • M0: no distant metastasis
    • M1: metastasis to distant organs (beyond regional lymph nodes)

Put your main focus on features that will determine the final stage. For example, if you see a lymph node involved by cancer, the presence or absence of lymphatic invasion is no longer critical, but rather the presence or absence of additional involved nodes or distant metastasis.

Radicality

If tumor is seen at edge of the sample, but it is not inked, consider confirming the finding with adjacent microtomy levels, especially if no ink is seen on an inked surgical margin. In this case, a separation artifact in top image has removed a surgical margin of connective tissue, seen on adjacent microtomy section in bottom image.

Determine if malignant cells are located close to, or even in, any surgical resection margins.

Lymphovascular invasion

Lymphovascular invasion should always be mentioned. When present at margins, it does not count as tumor extension.

Typing and grading

Also note "treatment effect", seen as fibroelastotic tissue, here with scattered remaining tumor cells.

Beyond determining overall malignancy diagnosis (such as adenocarcinoma), probable origin and staging, classification of tumors into a specific histopathologic type or grade is generally of relatively less value. In cases of clearly non-malignant tumors where it is difficult to determine the specific histopathologic type or grade, it is generally acceptable to conclude the evaluation and report it as such, unless the clinician specifically requests otherwise. For potentially malignant or high-risk tumors, typing and grading often still affects the management.

Additional slices

Additional slices are indicated in the following situations:

  • Re-excision does not identify tumor cells in a clearly non-radical primary excision or biopsy.[notes 1]
  • The most aggressive pattern is seen in the last available section, in which case more sections are indicated (from the same paraffin block if additional tissue is not available).

Reporting

For cancers, generally include a synoptic report, such as per College of American Pathologists (CAP) protocols at cap.org/protocols-and-guidelines.

  See also: General notes on reporting


Notes

  1. In such cases, step slices are taken rather than serial ones.
  1. For a full list of contributors, see article history. Creators of images are attributed at the image description pages, seen by clicking on the images. See Patholines:Authorship for details.

Main page

References

  1. 1.0 1.1 . Cancer staging. National Cancer Institute. Retrieved on 4 January 2013.
  2. 2.0 2.1 . General oncology. Amboss. Retrieved on 2020-01-29.

Image sources